Evicenter
MarkdownMedical informationP&T meetings
Inaxaplin (VX-147)

APOL1-mediated kidney disease

Launch
Not announced
Last updated
162 sources

Clinical evidence

AMPLITUDE

77 evidence topics · 27 sources

Objective
Location and study date
Study locations by country in the ClinicalTrials.gov record
CountryLocations listed in the record
United States“Alabama Locations”; “Arizona Locations”; “Arkansas Locations”; “California Locations”; “Connecticut Locations”; “District of Columbia Locations”; “Florida Locations”; “Georgia Locations”; “Illinois Locations”; “Indiana Locations”; “Iowa Locations”; “Kansas Locations”; “Louisiana Locations”; “Maryland Locations”; “Massachusetts Locations”; “Michigan Locations”; “Minnesota Locations”; “Mississippi Locations”; “Missouri Locations”; “Nevada Locations”; “New Jersey Locations”; “New Mexico Locations”; “New York Locations”; “North Carolina Locations”; “Ohio Locations”; “Pennsylvania Locations”; “Rhode Island Locations”; “South Carolina Locations”; “Tennessee Locations”; “Texas Locations”; “Virginia Locations”; “Washington Locations”; “Wisconsin Locations”
Belgium“Brussels, Belgium”; “Leuven, Belgium”
Brazil“Aracaju, Brazil”; “Belo Horizonte, Brazil”; “Botucatu, Brazil”; “Campinas, Brazil”; “Curitiba, Brazil”; “Fortaleza, Brazil”; “Goiânia, Brazil”; “Juiz de Fora, Brazil”; “Marília, Brazil”; “Monte Alegre, Brazil”; “Porto Alegre, Brazil”; “Recife, Brazil”; “Rio de Janeiro, Brazil”; “Salvador, Brazil”; “Santo André, Brazil”; “São José do Rio Preto, Brazil”; “São Paulo, Brazil”
Canada“Montreal, Canada”; “Toronto, Canada”
Colombia“Atlántico, Colombia”; “Bogotá, Colombia”; “Cali, Colombia”; “Cartagena, Colombia”; “Ibague, Colombia”; “Medellín, Colombia”
France“Créteil, France”; “Grenoble, France”; “Le Kremlin-Bicêtre, France”; “Limoges, France”; “Marseille, France”; “Paris, France”; “Pointe à Pitre, France”; “Saint-Ouen, France”; “Toulouse, France”
Ghana“Accra, Ghana”; “Cantonments, Ghana”; “Kumasi, Ghana”
Netherlands“Amsterdam, Netherlands”
Nigeria“Enugu, Nigeria”; “Ibadan, Nigeria”; “Idi-Araba, Nigeria”; “Ikeja, Nigeria”; “Lagos, Nigeria”
Portugal“Amadora, Portugal”; “Lisbon, Portugal”; “Loures, Portugal”
Puerto Rico“Mayagüez, Puerto Rico, 06680”; “Rio Piedras, Puerto Rico, 00935”; “San Juan, Puerto Rico, 00917”
Spain“Barcelona, Spain”; “Córdoba, Spain”; “Madrid, Spain”; “Seville, Spain”
United Kingdom“Basildon, United Kingdom”; “Bellshill, United Kingdom”; “Birmingham, United Kingdom”; “Carshalton, United Kingdom”; “Leicester, United Kingdom”; “London, United Kingdom”; “Manchester, United Kingdom”; “Nottingham, United Kingdom”
Study design
Independent data monitoring committee in the ClinicalTrials.gov data summarized by the EU register mirror
Eligibility criteria
Part A inclusion criteria: genotype, age, body size, proteinuria, and kidney function in the EU register record

“Subject has an APOL1 genotype of G1/G1, G2/G2, or G1/G2 obtained with a Vertex designated investigational clinical study assay.” (opens the source at this quote in a new tab)

“For Phase 2, subjects must be between the ages of 18 and 65 years at time of signing first ICF, inclusive. For Phase 3, subjects must be between the ages of 12 and 65 years at time of signing first ICF, inclusive.” (opens the source at this quote in a new tab)

“Pediatric subjects may be enrolled only after IDMC review of Phase 2 data is completed, the Phase 3 dose is selected, and a recommendation by the IDMC on the inclusion of pediatric subjects is made.” (opens the source at this quote in a new tab)

“Up to approximately 15% of the total number of subjects planned for enrollment may be >61 to ≤65 years of age at time of signing first ICF, inclusive.” (opens the source at this quote in a new tab)

“A BMI of 18 to 45 kg/m2, inclusive, and a total body weight ≥40 kg.” (opens the source at this quote in a new tab)

“A UPCR of ≥0.7 g/g to <10 g/g in the first morning void based on the average of 3 measurements collected on 3 separate days within a 7-day period, during the Screening Period.” (opens the source at this quote in a new tab)

“Estimated glomerular filtration rate (eGFR) ≥25 to < 75 mL/min/1.73 m2 during the Screening Period” (opens the source at this quote in a new tab)

Treatment
Investigational medicinal product and placebo in the EU register record
FieldQuoted record
Test product“VX-147 film-coated tablet”
Maximum daily dose“45 mg milligram(s)”
Maximum total dose“4860 mg milligram(s)”
Maximum duration of treatment“108 week(s)”
Orphan designation number“EMA/OD/0000090156”
Placebo“VX-147, Coated Placebo Tablet”
Study outcomes
Rationale for using percent change in UPCR at week 48 and eGFR slope as the primary endpoints
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary: study limitations

As of November 2026, no efficacy or safety results of AMPLITUDE have been published or posted: the registry record shows 522 participants enrolled, and the company states that data from the week 48 interim analysis are expected in early 2027. The only participant-level data reported are the APOL1 genotype distribution, mean age (42.7 years), and mean eGFR (42.8 mL/min/1.73 m2) of the 64 participants dosed as of the 2025 abstract; the dose-selection results of that portion and its safety data have not been reported. The accelerated approval pathway rests on the week 48 interim analysis of percent change in UPCR and eGFR slope, two surrogate endpoints; the final analysis of eGFR slope requires at least 2 years of eGFR data, and the composite clinical outcome (sustained eGFR decline of at least 30%, end-stage kidney disease, or death) is a secondary endpoint. The supporting surrogate-endpoint evidence comes mainly from other kidney diseases: the EMA notes that for rare diseases “support of efficacy may need to be provided by additional endpoints”, a 2025 review states for proteinuria short of complete remission in FSGS that “further work is needed to determine how such an endpoint should be defined”, and the only analysis specific to APOL1-mediated kidney disease is a real-world analysis of 128 participants. Eligibility required UPCR of 0.7 to less than 10 g/g and eGFR of 25 to less than 75 mL/min/1.73 m2 and excluded people with diabetes, transplantation, uncontrolled hypertension, or another known cause of kidney disease, so the results will not describe people with modest proteinuria or type 2 diabetes, whom the company describes as “populations not being studied in the AMPLITUDE trial”. The registered age range differs between records: the ClinicalTrials.gov record lists 10 to 65 years, and the EU register inclusion criteria list 12 to 65 years for phase 3. The registry lists 314 locations in 13 countries and territories, including the United States. In Part B, participants who complete Part A receive inaxaplin for an additional 96 weeks without a placebo group, and the definitions of the analysis populations have not been published.